AI in COPD diagnosis can support case finding, spirometry interpretation and equity while GOLD 2026 highlights validation and guideline gaps.
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
Maternal smoking and CC16 are linked to impaired lung development, lung function decline and emphysema progression, increasing lifelong COPD risk.
Expiratory flow-volume curve concavity predicts future respiratory symptoms but shows lower discriminatory accuracy for COPD incidence than FEV1/FVC.
Gut-lung axis microbiome analysis in stable COPD reveals distinct gut and lung microbiomes associated with airflow limitation, exacerbations and ICS use
BMI genetic factors and COPD are associated with decreased emphysema and increased airway wall thickness across quantitative and visual imaging phenotypes
Blood biomarkers including CC16, sRAGE and SPD identify pre-COPD lung function trajectories and may improve early COPD risk detection and prevention.
El estudio P4COPD investiga cómo predecir, prevenir y personalizar el manejo de la pre-EPOC en adultos jóvenes mediante medicina de precisión y biomarcadores.
The EXACERBANTES Study explores treatable traits in COPD exacerbations, aiming to improve risk assessment and support personalized clinical management.
GOLD and GLI provide a joint position on spirometry for diagnosing COPD, supporting the fixed FEV1/FVC ratio in the appropriate clinical context.
